Genexine, Inc (095700) Fair Value & Analysis
Healthcare · KR · Market cap 142B KRW
Fair value as of: Jul 6, 2026
From 1 valuation models · updated today
Fair value updated Jul 6, 2026 — revised from 24,415 KRW to 3,635 KRW (−85.1%) since Jun 24, 2026. Share price −28.8% over the past month.
Price vs Fair Value (12 months)
12‑month range 2,300 KRW – 7,100 KRW · fair‑value band 2,713 KRW – 5,426 KRW · the 2,490 KRW price screens below the 3,635 KRW fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Genexine, Inc (095700) currently trades at 2,490 KRW, while our model-based Fair Value estimate is 3,635 KRW — implying the stock looks roughly 46.0% undervalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at 5.8B KRW. Revenue grew 199.6% year over year. It earns a return on equity of -17.3%. Net debt stands at 98.6B KRW. Fundamentals as of Jul 6, 2026
Our scenario range runs from 2,713 KRW (bear case) to 5,426 KRW (bull case); at 2,490 KRW, the current price sits below that range. The share trades about 67% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at 46%, 095700 screens cheaper than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Genexine, Inc reported revenue of 4.6B KRW in FY2025 versus 36.8B KRW in FY2021, a compound −40.6%/yr. Reported net income was −27.2B KRW in FY2025.
Is 095700 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$102.95 | A$126.79 | +23% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| Moderna, Inc M1RN34 | R$14.75 | R$4.91 | -67% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Genexine, Inc (095700) undervalued?
What is the fair value of 095700?
What is the quality score of 095700?
What is the revenue of Genexine, Inc (095700)?
What is the net profit margin of 095700?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.